|
Name |
Chartarlactam A
|
Molecular Formula | C23H29NO5 | |
IUPAC Name* |
3,4'-dihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3H-furo[2,3-e]isoindole]-6',8'-dione
|
|
SMILES |
CC1CCC2C(C(CCC2(C13CC4=C(C=C5C(=C4O3)C(=O)NC5=O)O)C)O)(C)C
|
|
InChI |
InChI=1S/C23H29NO5/c1-11-5-6-15-21(2,3)16(26)7-8-22(15,4)23(11)10-13-14(25)9-12-17(18(13)29-23)20(28)24-19(12)27/h9,11,15-16,25-26H,5-8,10H2,1-4H3,(H,24,27,28)
|
|
InChIKey |
JGLXRTLGZYXTLO-UHFFFAOYSA-N
|
|
Synonyms |
Chartarlactam A; 1528745-88-1; 3,4'-dihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3H-furo[2,3-e]isoindole]-6',8'-dione
|
|
CAS | NA | |
PubChem CID | 137796386 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 399.5 | ALogp: | 3.7 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 95.9 | Aromatic Rings: | 5 |
Heavy Atoms: | 29 | QED Weighted: | 0.574 |
Caco-2 Permeability: | -4.948 | MDCK Permeability: | 0.00001450 |
Pgp-inhibitor: | 0.038 | Pgp-substrate: | 0.974 |
Human Intestinal Absorption (HIA): | 0.015 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.035 |
Blood-Brain-Barrier Penetration (BBB): | 0.771 | Plasma Protein Binding (PPB): | 91.15% |
Volume Distribution (VD): | 0.742 | Fu: | 6.99% |
CYP1A2-inhibitor: | 0.073 | CYP1A2-substrate: | 0.434 |
CYP2C19-inhibitor: | 0.155 | CYP2C19-substrate: | 0.673 |
CYP2C9-inhibitor: | 0.519 | CYP2C9-substrate: | 0.841 |
CYP2D6-inhibitor: | 0.085 | CYP2D6-substrate: | 0.29 |
CYP3A4-inhibitor: | 0.212 | CYP3A4-substrate: | 0.198 |
Clearance (CL): | 10.543 | Half-life (T1/2): | 0.093 |
hERG Blockers: | 0.034 | Human Hepatotoxicity (H-HT): | 0.283 |
Drug-inuced Liver Injury (DILI): | 0.092 | AMES Toxicity: | 0.036 |
Rat Oral Acute Toxicity: | 0.719 | Maximum Recommended Daily Dose: | 0.894 |
Skin Sensitization: | 0.193 | Carcinogencity: | 0.027 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.012 |
Respiratory Toxicity: | 0.455 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005396 | 0.753 | D0L2LS | 0.263 | ||||
ENC002673 | 0.753 | D0Z1XD | 0.261 | ||||
ENC003020 | 0.753 | D0Q6NZ | 0.261 | ||||
ENC003789 | 0.753 | D03XOC | 0.259 | ||||
ENC002996 | 0.753 | D04GJN | 0.256 | ||||
ENC002995 | 0.753 | D0I2SD | 0.256 | ||||
ENC003008 | 0.657 | D0W2EK | 0.254 | ||||
ENC002034 | 0.657 | D0IL7L | 0.250 | ||||
ENC002992 | 0.657 | D0IX6I | 0.250 | ||||
ENC003014 | 0.622 | D0U3GL | 0.250 |